| Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
|
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
| Understanding infectious complications in patients with lower risk myelodysplastic syndromes: a step towards improving survival |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice. |
|
Blood Advances |
Aplastic Anemia |
| Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
|
Haemotologica |
Myelodysplastic Syndromes (MDS) |
| Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
|
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia |
|
Blood Cancer Journal |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
